Clinical trials in Lille – page 88

1 329 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Lille at a glance

1 329

clinical trials

Research sites3

Quick filters

1 329 trials in Lille

Open in trial search

Amyotrophic lateral sclerosis

Not recruiting

Study on the Effects of NX210c and Glucose in Adults with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

Study on the Effects of NX210c and Glucose in Adults with Amyotrophic Lateral Sclerosis (ALS)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Glucose
Sponsor:Axoltis Pharma

Contact Research Centre

Migraine+1

Not recruiting

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo

Study of Eptinezumab as Add-on Treatment for Prevention of Migraine in Adults with Both Migraine and Medication Overuse Headache

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Eptinezumab
Sponsor:H. Lundbeck A/S

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Oesophageal squamous cell carcinoma

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

France

Participants:18–64 years · 65+ years
Substances:Utreloxastat
Sponsor:PTC Therapeutics Inc.

Contact Research Centre

Anti-neutrophil cytoplasmic antibody positive vasculitis+1

Not recruiting

Study on Continuing or Stopping Immunosuppressive Therapy with Rituximab in Patients with ANCA Vasculitis and End-stage Kidney Disease

Registered drugNo placebo

Study on Continuing or Stopping Immunosuppressive Therapy with Rituximab in Patients with ANCA Vasculitis and End-stage Kidney Disease

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Centre Hospitalier Departemental Vendee

Contact Research Centre

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Elranatamab
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

Advanced cancer therapies
Targeted molecular treatments
Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

Neurodegenerative diseases
Movement disorders
Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

Inflammatory bowel diseases
Immunotherapy approaches
Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to France All countries